98%
921
2 minutes
20
Skin toxicity is a common safety concern associated with drugs that inhibit epidermal growth factor receptors as well as other targets involved in epidermal growth and differentiation. Recently, the use of a three-dimensional reconstructed human epidermis model enabled large-scale drug screening and showed potential for predicting skin toxicity. Although a decrease in epidermal thickness was often observed when the three-dimensional reconstructed tissues were exposed to drugs causing skin toxicity, the thickness evaluation of epidermal layers from a pathologist was subjective and not easily reproducible or scalable. In addition, the subtle differences in thickness among tissues, as well as the large number of samples tested, made cross-study comparison difficult when a manual evaluation strategy was used. The current study used deep learning and image-processing algorithms to measure the viable epidermal thickness from multiple studies and found that the measured thickness was not only significantly correlated with a pathologist's semi-quantitative evaluation but was also in close agreement with the quantitative measurement performed by pathologists. Moreover, a sensitivity of 0.8 and a specificity of 0.75 were achieved when predicting the toxicity of 18 compounds with clinical observations with these epidermal thickness algorithms. This approach is fully automated, reproducible, and highly scalable. It not only shows reasonable accuracy in predicting skin toxicity but also enables cross-study comparison and high-throughput compound screening.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajpath.2021.12.007 | DOI Listing |
Biomaterials
August 2025
Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, 90095, USA. Electronic address:
Wearable bioelectronics have transformed modern biomedical applications by enabling seamless integration with biological tissues, providing continuous, comprehensive, and personalized healthcare. Skin cancer, particularly melanoma, poses a significant clinical challenge due to its high metastatic potential and associated mortality. Traditional diagnostic approaches face limitations in accuracy, accessibility, and reproducibility, while existing treatments are often constrained by systemic toxicity and therapeutic resistance.
View Article and Find Full Text PDFPLoS One
September 2025
Department Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Tattoos and permanent make-up (PMU) gain increasing popularity among the general population. There are indications that pigments or their fragments may translocate within the body, however knowledge about possible systemic adverse effects related to tattoos is very limited. We investigated the prevalence of systemic chronic health effects including cardiovascular diseases, cancer and liver toxicity and their relationship with the presence and characteristics of tattoos and PMU as part of the LIFE-Adult-study, a population-based cohort study.
View Article and Find Full Text PDFBioimpacts
July 2025
Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Vitiligo, a chronic autoimmune disorder characterized by the presence of depigmented skin patches, remains a therapeutic challenge due to its multifactorial pathogenesis and the absence of highly effective treatment options. Although the exact etiology of vitiligo is not fully understood, factors such as genetic factors, oxidative stress, autoimmunity, and inflammation are implicated in the destruction of melanocytes. Current therapeutic strategies primarily focus on modulating immune responses and alleviating oxidative stress.
View Article and Find Full Text PDFCrit Rev Oncol Hematol
September 2025
Division of Thoracic Oncology, European Institute of Oncology, IEO, IRCCS, 20141, Milan, Italy.
Amivantamab, a bispecific EGFR-MET antibody, has demonstrated efficacy in EGFR-mutant non-small cell lung cancer (NSCLC) across multiple trials and is poised to enter first-line therapy. However, as with EGFR-targeted therapies, amivantamab is associated with distinctive cutaneous toxicities. This perspective summarizes clinical evidence on the frequency, nature, and severity of skin-related adverse events from key studies, outlining how, despite concerns initially raised among clinicians about its tolerability in routine practice, clinical experience indicates that amivantamab's cutaneous toxicities are manageable with proactive strategies and education.
View Article and Find Full Text PDFRadiother Oncol
September 2025
Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland, UK.
Introduction: Preclinical evidence has demonstrated the potential of FLASH radiotherapy (FLASH-RT) to spare normal tissues compared to conventional (CONV) exposures. Most FLASH studies have used ultra-high dose rate (>40 Gy/sec) electrons and protons whilst comparatively few studies have reported photon FLASH responses. Given the widespread use of photons clinically, there is a need to characterise the FLASH effect using photons.
View Article and Find Full Text PDF